[go: up one dir, main page]

ATE374642T1 - Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose - Google Patents

Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose

Info

Publication number
ATE374642T1
ATE374642T1 AT01966399T AT01966399T ATE374642T1 AT E374642 T1 ATE374642 T1 AT E374642T1 AT 01966399 T AT01966399 T AT 01966399T AT 01966399 T AT01966399 T AT 01966399T AT E374642 T1 ATE374642 T1 AT E374642T1
Authority
AT
Austria
Prior art keywords
antagonists
treat stenosis
migration
specific
smooth muscle
Prior art date
Application number
AT01966399T
Other languages
English (en)
Inventor
Mary Gerritsen
Mark Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE374642T1 publication Critical patent/ATE374642T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT01966399T 2000-09-01 2001-08-29 Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose ATE374642T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22967900P 2000-09-01 2000-09-01
US26551601P 2001-01-31 2001-01-31
US09/940,101 US20020119148A1 (en) 2000-09-01 2001-08-27 ErbB4 antagonists

Publications (1)

Publication Number Publication Date
ATE374642T1 true ATE374642T1 (de) 2007-10-15

Family

ID=27397993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01966399T ATE374642T1 (de) 2000-09-01 2001-08-29 Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose

Country Status (12)

Country Link
US (6) US20020119148A1 (de)
EP (1) EP1351744B1 (de)
JP (1) JP2004507559A (de)
AT (1) ATE374642T1 (de)
AU (2) AU8691801A (de)
CA (1) CA2420062C (de)
DE (1) DE60130797T2 (de)
DK (1) DK1351744T3 (de)
ES (1) ES2295202T3 (de)
HK (1) HK1059404A1 (de)
IL (2) IL154495A0 (de)
WO (1) WO2002018444A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US20040156835A1 (en) * 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
AU2003237367A1 (en) * 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
ES2376165T3 (es) 2002-07-15 2012-03-09 F. Hoffmann-La Roche Ag Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
JP4527388B2 (ja) * 2003-12-11 2010-08-18 東洋鋼鈑株式会社 ポリペプチドとレセプターとの相互作用を検出する方法、該検出する方法を用いてリガンドまたはリガンド変異体をスクリーニングする方法および該検出する方法を用いる診断方法
EP2286844A3 (de) 2004-06-01 2012-08-22 Genentech, Inc. Antikörper-Arzneimittelkonjugate und Verfahren
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR20080004480A (ko) * 2005-03-07 2008-01-09 타게티드 몰레큘라 다이아그노스틱스, 엘엘씨 티로신 키나제 억제제 조성물, 그의 제조 방법 및 이를이용한 질병 치료 방법
DK2716301T3 (en) * 2007-02-16 2017-07-31 Merrimack Pharmaceuticals Inc ANTIBODIES AGAINST ERBB3 AND APPLICATIONS THEREOF
CA2719201A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
PE20120015A1 (es) * 2008-08-15 2012-01-26 Merrimack Pharmaceuticals Inc Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
KR101789338B1 (ko) 2008-11-25 2017-10-23 제넨테크, 인크. 이소형 특이적 항-ｈｅｒ４ 항체
CN102356092B (zh) * 2009-03-20 2014-11-05 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
WO2011069104A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
LT3095871T (lt) 2010-02-08 2019-05-27 Regeneron Pharmaceuticals, Inc. Bendros lengvosios grandinės pelė
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2011107100A1 (en) 2010-03-03 2011-09-09 Aarhus Universitet Methods and compositions for regulation of herv4
CA2792327C (en) 2010-03-11 2019-09-24 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
EP2640831A1 (de) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Die bindungsstelle eines influenzaneutralisierenden antikörpers nachahmende influenzavirusneutralisierungsmittel
PL3572517T3 (pl) 2011-08-05 2021-10-04 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym uniwersalnym łańcuchem lekkim
KR20140054268A (ko) 2011-08-26 2014-05-08 메리맥 파마슈티컬즈, 인크. 탠덤 fc 이중특이적 항체
MA38164B1 (fr) * 2012-11-08 2018-11-30 Hoffmann La Roche Protéines de liaison à l'antigène anti-her3/her4 se liant à la boucle en épingle à cheveux beta
US9725512B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. HER3 antibodies binding to the beta-hairpin of HER3
WO2014138449A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
MX2016012274A (es) 2014-03-21 2017-05-23 Regeneron Pharma Animales no humanos que producen proteinas de union de dominio simple.
FR3020063A1 (fr) * 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
EP3143048B1 (de) 2014-05-14 2019-08-28 F. Hoffmann-La Roche AG An die beta-haarnadel von her3 bindende anti-her3-antikörper
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2037440A1 (en) 1990-03-02 1991-09-03 Gregory D. Plowman Her3: a novel egf receptor homolog
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
DK0790997T3 (da) 1994-11-14 2000-08-21 Warner Lambert Co 6-Aryl-pyrido[2,3-d]pyrimidiner og napthyridiner til hæmning af protein-tyrosin-kinase-fremkaldt celleproliferation
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
BR9710357A (pt) * 1996-07-12 1999-08-17 Genentech Inc Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo
DE69732711T2 (de) * 1996-07-12 2006-03-16 Genentech, Inc., South San Francisco Gamma-heregulin
ATE371673T1 (de) * 1996-11-27 2007-09-15 Genentech Inc Affinitätsreinigung von polypeptiden an einer protein a-matrix
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
US6994856B1 (en) * 1997-07-24 2006-02-07 Genentech, Inc. ErbB4 receptor-specific neuregulin related ligands and uses therefor
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
WO2000031048A1 (en) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
WO2001094413A2 (en) * 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists

Also Published As

Publication number Publication date
IL154495A0 (en) 2003-09-17
JP2004507559A (ja) 2004-03-11
CA2420062A1 (en) 2002-03-07
US20100190964A1 (en) 2010-07-29
US20070092513A1 (en) 2007-04-26
DE60130797D1 (de) 2007-11-15
US20060093603A1 (en) 2006-05-04
US7704498B2 (en) 2010-04-27
HK1059404A1 (en) 2004-07-02
WO2002018444A3 (en) 2003-07-31
CA2420062C (en) 2014-04-01
DE60130797T2 (de) 2008-08-07
DK1351744T3 (da) 2008-02-11
US7332579B2 (en) 2008-02-19
EP1351744B1 (de) 2007-10-03
US20020119148A1 (en) 2002-08-29
EP1351744A2 (de) 2003-10-15
WO2002018444A2 (en) 2002-03-07
ES2295202T3 (es) 2008-04-16
AU8691801A (en) 2002-03-13
AU2001286918B2 (en) 2006-12-21
IL154495A (en) 2009-12-24
US20040052786A1 (en) 2004-03-18
US20090068205A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
ATE374642T1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE60045474D1 (de) Neues verfahren zum erschaffen von proteinkinase-inhibitoren
ATE376446T1 (de) Verwendung von n-hydroxyalkyl-o-benzylchitosanen zur haarbehandlung
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
ATE255420T1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
DE60139457D1 (de) Ungen unter verwendung einer geweberisikokarte
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
EP1023005A4 (de) Verfahren zum beschichten von stents mit dna sowie zur in vivo expression von rekombinanten genen von mit dna beschichteten
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE60033576D1 (de) Methoden zum screening knochenmorphogenetishemimetika
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE501730T1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
ATE239497T1 (de) Verwendung von urodilatin zur behandlung chronischer niereninsuffizienz mit nierenrestfunktionen
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE409732T1 (de) Methoden zur vorbehandlung von schuhen
ATE258064T1 (de) Verwendung von antileukoprotease zur behandlung von endometriose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1351744

Country of ref document: EP